Drug
Part 2
Part 2 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 60.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
60.0%
Based on 3 completed trials
Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_2
1
20%
Ph not_applicable
2
40%
Ph phase_1
2
40%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
N/ANon-phased studies
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 21 (20.0%)
N/A2 (40.0%)
Trials by Status
completed360%
terminated240%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates
NCT06930872
terminatedphase_1
A Study in Patients With Advanced Breast Cancer
NCT04942054
terminatedphase_2
Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo
NCT04521296
completednot_applicable
Tobacco Cessation in Postmenopausal Women
NCT01210586
completednot_applicable
Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advance Care Planning Program in Gastrointestinal Oncology Patients
NCT01912131
Clinical Trials (5)
Showing 5 of 5 trials
NCT06930872Phase 1
Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates
NCT04942054Phase 1
A Study in Patients With Advanced Breast Cancer
NCT04521296Phase 2
Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo
NCT01210586Not Applicable
Tobacco Cessation in Postmenopausal Women
NCT01912131Not Applicable
Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advance Care Planning Program in Gastrointestinal Oncology Patients
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5